MedTrace Logo

Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction of Midface Contour Deficiencies

NCT05262777 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 211

Last updated 2024-04-09

No results posted yet for this study

Summary

A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness of GP0112 for cheek augmentation and correction of midface contour deficiencies

Conditions

  • Cheek Wrinkles
  • Midface Contour Deficiencies

Interventions

DEVICE

GP0112

Injectable gel

DEVICE

Restylane Lyft Lidocaine

Injectable gel

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Study Director · Galderma R&D

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-02
Primary Completion
2023-01-17
Completion
2024-03-05

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05262777 on ClinicalTrials.gov